Clinical trial
Phase IV, Multicenter, Double-blind, Randomized, Controlled, Parallel-group, Trial to Evaluate the Efficacy and Safety of Dozolamide 2%/Timolol 0,5% PF vs Dorzolamide 2%/Timolol 0,5% BAK-preserved in OAG or OH
NCT05857267 is registered in ClinicalTrials.gov with Laboratorios Poen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IV, Multicenter, Double-blind, Randomized, Controlled, Parallel-group, Trial to Evaluate the Efficacy and Safety of Dozolamide 2%/Timolol 0,5% PF vs Dorzolamide 2%/Timolol 0,5% BAK-preserved in OAG or OH
- Lead sponsor
- Laboratorios Poen
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 7, 2023
- Completion date
- November 4, 2024
- Enrollment
- 84 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.